Business · 06/10/2026
FDA Classifies High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System
The FDA has classified the high throughput DNA sequencing for hereditary cancer predisposition assessment test system into Class II, requiring special controls, as part of its efforts to regulate the device.
Source: Federal Register — Health and Human ServicesOpen original release →